Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
6.
Dermatol Online J ; 26(5)2020 May 15.
Article in English | MEDLINE | ID: mdl-32621706

ABSTRACT

We present a 30-year-old woman with a solitary circumscribed neuroma (also known as palisaded encapsulated neuroma) diagnosed after surgical excision. We describe the histopathologic correlation and the dermoscopic features we found in this tumor, which have not been previously reported in the literature to our knowledge.


Subject(s)
Neuroma/pathology , Skin Neoplasms/pathology , Adult , Cheek/pathology , Dermoscopy , Female , Humans
7.
J Assist Reprod Genet ; 37(9): 2081-2092, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32578032

ABSTRACT

PURPOSE: Intracytroplasmatic sperm injection (ICSI) is a common procedure used to improve reproductive results, even among couples without male factor infertility. However, the evidence available is still uncertain on the possible advantages and deficiencies that this procedure may have in patients with no formal indication for ICSI. METHODS: A SWOT (strengths, weaknesses, opportunities, threats) analysis examines the possible advantages and deficiencies of performing ICSI in these patients with no formal indication. RESULTS: The evidence suggests that ICSI is not justified for non-male factor infertile couples requiring in vitro conception. One of the major strengths associated to the procedure is the virtual elimination of cases further complicated by total fertilization failure and a combination between IVF and ICSI on sibling oocytes has been advised in the literature. Greater technical difficulties, higher costs and performing an unnecessary invasive technique in some cases represent some of the weaknesses of the procedure, and questions regarding safety issues should not be ruled out. CONCLUSION: Despite the widespread use of ICSI in patients without a formal diagnosis of male factor infertility, evidence demonstrating its effectiveness in this population is still lacking. Additional large and well-designed randomized controlled trials are needed to clarify definitive indications for ICSI in non-male factor infertility.


Subject(s)
Fertilization in Vitro/trends , Infertility, Male/genetics , Sperm Injections, Intracytoplasmic/trends , Spermatozoa/growth & development , Adult , Embryo Transfer , Female , Humans , Infertility, Male/therapy , Male , Oocytes/cytology , Oocytes/growth & development , Pregnancy , Pregnancy Rate , Semen/metabolism
10.
Reprod Biomed Online ; 37(6): 709-715, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30527061

ABSTRACT

Hysteroscopic septum resection in women with unfavourable reproductive and clinical outcomes has become common practice worldwide to improve reproductive results. No clear evidence on the possible advantages and drawbacks of this procedure has been published. In this opinion paper, based on a SWOT (strengths, weaknesses, opportunities, threats) analysis, the different aspects of this strategy are evaluated. Currently, no level 1 published evidence supports uterine resection in women with septate uterus. Clinical evidence from the studies analysed matches the more recent guidelines and suggests an improvement in reproductive outcomes after hysteroscopic resection of the septum, particularly in infertile women and women who have experienced recurrent miscarriages. In a patient with no history of infertility or prior pregnancy loss, it may be reasonable to consider septum incision after counselling about the potential risks and benefits of the procedure. Published clinical data in favour of the intervention, however, are based on studies with important methodological limitations. In this situation, the clinician and patient should reach an agreement together, based on the pros and cons of this intervention. Well-designed randomized controlled trials are required to confirm the clinical benefits and cost-effectiveness of this procedure.


Subject(s)
Gynecologic Surgical Procedures/statistics & numerical data , Infertility, Female/surgery , Uterus/surgery , Abortion, Habitual , Abortion, Induced , Adult , Female , Gynecologic Surgical Procedures/adverse effects , Humans , Hysteroscopy , Practice Guidelines as Topic , Reproduction , Reproductive Medicine , Treatment Outcome , Uterus/abnormalities
12.
Clin Exp Dermatol ; 41(6): 667-70, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27378586

ABSTRACT

Elastosis perforans serpiginosa (EPS) is a rare skin disorder characterized by transepidermal elimination of abnormal elastic fibres. We present a new case of D-penicillamine (DPA)-induced EPS, and describe the clinical, dermoscopic, histopathological and direct immunofluorescence (DIF) findings. A 33-year-old woman receiving treatment with DPA presented with annular skin lesions. Digital dermoscopy of the lesions showed a central area of pink and yellowish discolouration with keratotic papules in the periphery, surrounded by a white halo, disposed in a way that resembled the islands of an archipelago. Other lesions showed a white to yellow central colouration and 'chrysalides' surrounding the keratotic plugs. Linear and granular deposits of IgG attached to the abnormal elastic fibres were seen with DIF. Dermoscopy can be helpful in the diagnosis of EPS. Moreover, DIF findings in skin biopsies of this case support the immune-mediated pathogenesis of EPS.


Subject(s)
Dermoscopy/methods , Fluorescent Antibody Technique, Direct/methods , Penicillamine/adverse effects , Skin Diseases/chemically induced , Adult , Chelating Agents/adverse effects , Chelating Agents/therapeutic use , Elastic Tissue/pathology , Female , Hepatolenticular Degeneration/complications , Hepatolenticular Degeneration/drug therapy , Hepatolenticular Degeneration/pathology , Humans , Penicillamine/administration & dosage , Penicillamine/therapeutic use , Rare Diseases , Skin/pathology , Skin Diseases/pathology
14.
Lupus ; 25(2): 204-8, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26385224

ABSTRACT

Patients with autoimmune disorders are predisposed to develop a second immunologic disease, frequently with systemic involvement. We present a patient who developed lesions of discoid lupus erythematosus (DLE) limited to the face, and, concurrently, a linear morphoea involving her right axilla. No criteria for systemic lupus erythematosus or systemic scleroderma were present in the patient. To our knowledge, no patients with concomitant DLE and linear morphoea, without systemic involvement, have been previously reported in the literature.


Subject(s)
Lupus Erythematosus, Discoid/pathology , Scleroderma, Localized/pathology , Skin Diseases/pathology , Arm/pathology , Face/pathology , Female , Humans , Middle Aged , Mixed Connective Tissue Disease/pathology
17.
Hum Reprod ; 28(3): 794-800, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23293223

ABSTRACT

STUDY QUESTION: Does female obesity affect the dynamic parameters of embryo quality assessed by time-lapse analysis? SUMMARY ANSWER: Female obesity does not affect the dynamic embryo quality as determined by image acquisition and time-lapse analysis. WHAT IS KNOWN ALREADY: Female obesity impairs natural and assisted reproduction but there is no agreement on the specific contribution of gametes, embryos or endometrial receptivity. In this preliminary study the dynamic parameters of embryo quality are assessed for the first time by time-lapse analysis. STUDY DESIGN, SIZE, DURATION: Two-year cohort retrospective study comparing embryos from three groups of patients according to the presence of infertility and/or obesity. PARTICIPANTS AND SETTING: Participants attended a University-affiliated private clinic where ICSI was performed. Using an IVF incubator with a built-in camera designed to automatically acquire images at defined time points, we monitored individual embryos from 89 patients: 71 embryos from 13 obese infertile women, 242 embryos from 45 normoweight infertile women and 111 embryos from 31 normoweight fertile oocyte donors. The chronological pattern of cell divisions (timings of cell cleavages) and other morphologic features (time-dependent cell size and nucleation) was recorded. MAIN RESULTS AND THE ROLE OF CHANCE: Embryos from obese and normoweight infertile women showed similar cleavage patterns, but occurring more slowly, to those from fertile donors. These differences were statistically significant for t2 (time of cleavage to two-blastomere embryo) (P = 0.016), t3 (P = 0.014), t4 (P = 0.003) and t5 (P = 0.040). LIMITATIONS, REASONS FOR CAUTION: These are preliminary data from a retrospective analysis with a limited sample size. GENERALIZABILITY TO OTHER POPULATIONS: Not recommended until further studies using time-lapse analysis of a larger sample have been performed. STUDY FUNDING/COMPETING INTEREST(S): None.


Subject(s)
Blastocyst/pathology , Ectogenesis , Infertility, Female/complications , Infertility, Female/pathology , Obesity/complications , Adult , Body Mass Index , Cell Division , Cell Size , Cohort Studies , Embryo Culture Techniques , Female , Humans , Image Processing, Computer-Assisted , Infertility, Female/therapy , Kinetics , Oocyte Donation , Retrospective Studies , Time-Lapse Imaging
18.
BJOG ; 120(1): 50-7, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22882759

ABSTRACT

OBJECTIVE: Previous trials have shown little benefit for preventing preterm birth in twin pregnancies using 90-200 mg of daily vaginal natural progesterone. Higher doses have not been tested. Our aim was to determine the efficacy and safety of two different daily doses of vaginal natural progesterone (200 and 400 mg), compared with placebo, for preventing preterm birth in unselected twin pregnancies. DESIGN: Randomised controlled double-blind multicentre trial (1:1:1). SETTING: The study was carried out in five university centres from Valencia, Murcia and Alicante (Spain). POPULATION: Women with dichorionic diamniotic twin pregnancies. METHODS: The women self-inserted two vaginal pessaries daily, containing placebo (n = 96), 200 mg of natural progesterone (n = 97) or 400 mg of natural progesterone (n = 97), from 20 to 34 weeks of gestation or delivery. Randomisation was performed by an external centre. Data were analysed on an intention-to-treat basis. MAIN OUTCOME MEASURE: Preterm birth rate. RESULTS: The baseline characteristics for placebo and progesterone groups were similar. Comparison of the three groups and analysis of progesterone-treated versus untreated women showed similar pregnancy and neonatal outcomes. The proportion of preterm and very preterm births, low birthweight, perinatal mortality and neonatal morbidity showed no differences between the three groups. Similar results were also obtained when comparing the 200- versus 400-mg progesterone groups. No serious adverse effects were encountered. CONCLUSIONS: Vaginal progesterone therapy was generally well tolerated, but failed to prevent preterm births in unselected dichorionic diamniotic twin pregnancies. The 400-mg progesterone dose offered no advantages over the 200-mg regimen.


Subject(s)
Pregnancy, Twin , Premature Birth/prevention & control , Progesterone/administration & dosage , Progestins/administration & dosage , Administration, Intravaginal , Adult , Birth Weight , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Medication Adherence , Pessaries , Pregnancy , Pregnancy Outcome , Self Care
19.
Hum Reprod ; 25(7): 1713-21, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20501469

ABSTRACT

BACKGROUND: The aim of the present study was to evaluate the implication of male factor, in terms of sperm DNA oxidation and fragmentation, and Y chromosome microdeletions in recurrent spontaneous abortion (RSA) of unknown origin in a strictly selected cohort. METHODS: A prospective cohort study was carried out in a private university-affiliated setting. Three groups, each comprised of 30 males, were compared. The first was formed by healthy and fertile sperm donors (SD) with normal sperm parameters (control group), the second by men presenting severe oligozoospermia (SO) without RSA history, and the third by men from couples who had experienced idiopathic RSA. Frequency of Y chromosome microdeletions and mean sperm DNA fragmentation and oxidation were determined. RESULTS: Y chromosome microdeletions were not detected in any of the males enrolled in the study. Moreover, sperm DNA oxidation measurements were not demonstrated to be relevant to RSA. Interestingly, sperm DNA fragmentation was higher in the SO group than in the RSA and the SD groups, and also higher in the RSA group compared with the SD group, but lacked an adequate predictive power to be employed as a discriminative test of RSA condition. CONCLUSIONS: Sperm DNA features and Y chromosome microdeletions do not seem to be related to RSA of unknown origin. Other molecular features of sperm should be studied to determine their possible influence on RSA. Clinicaltrials.gov reference: NCT00447395.


Subject(s)
Abortion, Habitual/genetics , Chromosome Deletion , Chromosomes, Human, Y , DNA Fragmentation , Oxidative Stress , Spermatozoa/physiology , Adolescent , Adult , Age Factors , Case-Control Studies , DNA/metabolism , Female , Humans , Male , Oxidation-Reduction , Pregnancy , Prospective Studies , Semen Analysis , Tissue Donors
20.
Reprod Biomed Online ; 19(4): 486-92, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19909588

ABSTRACT

The use of gonadotrophin-releasing hormone (GnRH) agonists for triggering ovulation remains controversial. The primary objective of this study was to evaluate the incidence of ovarian hyperstimulation syndrome (OHSS) following GnRH agonist versus recombinant human chorionic gonadotrophin (HCG) as methods for triggering ovulation. A second aim was to compare the clinical outcome and embryo quality according to the two procedures. The cycle characteristics of 100 oocyte donors undergoing ovarian stimulation and IVF outcomes of their 100 oocyte recipients were analysed. Donors were prospectively randomized into two groups on the last day of ovarian stimulation: Group I received a single bolus of 0.2 mg of triptorelin and Group II received 250 microg of recombinant HCG. No differences were observed in the number of oocytes retrieved or in the proportion of metaphase II oocytes between the groups. The OHSS rate was higher in donors that received recombinant HCG ( P = 0.003). Moreover, there was no significant difference between IVF parameters and outcome in the two groups. In conclusion, a GnRH agonist effectively triggers the final oocyte maturation in oocyte donors without negatively affecting implantation, pregnancy or miscarriage rates. Moreover, this regime effectively eliminates the risk of OHSS in this group of women.


Subject(s)
Chorionic Gonadotropin/therapeutic use , Gonadotropin-Releasing Hormone/agonists , Oocyte Donation/methods , Ovulation Induction/methods , Recombinant Proteins/therapeutic use , Triptorelin Pamoate/therapeutic use , Adolescent , Adult , Female , Fertilization in Vitro , Humans , Ovarian Hyperstimulation Syndrome/epidemiology , Ovarian Hyperstimulation Syndrome/prevention & control , Pregnancy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...